Group 1 - The core viewpoint of the article highlights the significant stock price increase of BGM, which rose by 10.86% to $11.13 per share, with a total market capitalization of $2.047 billion as of July 29 [1] - Financial data shows that BGM's total revenue reached $14.3114 million for the period ending March 31, 2025, representing a year-on-year growth of 13.92%, while the net profit attributable to shareholders was -$0.8612 million, a decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, biorefining, and healthcare [1] Group 2 - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human antibiotics and the global livestock industry [1] - Tetracycline raw materials support the production of human antibiotics and ensure the safety of poultry and seafood in the livestock sector [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1]
博美集团上涨10.86%，报11.13美元/股，总市值20.47亿美元